Hormonal
GLP-1/GIP receptor agonists (liraglutide, semaglutide, tirzepatide) produce significant weight loss (8-21%) but discontinuation leads to rapid weight regain (approx. two-thirds) and return of cardiovascular risk factors, necessitating long-term maintenance strategies.
GLP-1 medications are highly effective for weight loss but are not a one-time fix. You must plan for long-term use or a structured maintenance program to prevent weight regain. Discuss with your doctor how to manage side effects (like nausea) through diet and titration, and ensure you have a plan for ongoing care, as stopping the medication often leads to regaining two-thirds of the lost weight.
At one year post withdrawal of semaglutide, two-thirds of weight lost is regained and cardiovascular disease (CVD) risk factors return to baseline [72], suggesting ongoing treatment and monitoring is required to maintain improvements...
Why this rating
Supported by multiple large-scale randomized controlled trials (SCALE, STEP, SURPASS, SURMOUNT) cited in the review.
Source
What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?
María Gómez‐Martín et al. · Current Obesity Reports · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →